Clinical research
Our research trials are conducted with the highest level of honesty and integrity.
Contributions to a patient’s health and well-being are important — and patient safety and privacy are our priorities.
Meet the research team
Ben Carey
Research Supervisor
Madilyn Hoff
Study Coordinator
Clinical trials at Central Ohio Urology Group
Bladder cancer
Sunrise-3:
(closed for enrollment)
A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants with BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC) (SunRISe-3)
Able-41:
(open for enrollment)
Adstiladrin: Early Utilization and Outcomes in the Real World Setting in the United States
Sunrise-5:
(open for enrollment)
A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG)
Prostate cancer
ProvONE:
(open for enrollment)
Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T
Merck-004:
(open for enrollment)
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA
Libertas:
(closed for enrollment)
A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC
Replace-CV:
(closed for enrollment)
Relugolix Versus Leuprolide in Patients With Prostate Cancer: A Randomized, Open-Label Study to Assess Major Adverse Cardiovascular Events (REPLACE-CV)
ExoDx:
(open for enrollment)
Prostate Evaluation in Active Surveillance Patient Population
Optyx:
(open for enrollment)
A Multi-Center, Prospective, Observational Study of Patients Being Treated With ORGOVYX (OPTYX)
Bladder pain
Ironwood C330-201:
(open for enrollment)
Phase 2 Study of IW 3300 for the Treatment of Bladder Pain in Subjects with Interstitial Cystitis/Bladder Pain Syndrome